Lorcaserin Safety Questions Can Be Answered In Post-Market Study, Panel Tells FDA

FDA’s Endocrinologic and Metabolic Advisory Committee backs approval of Arena’s weight-loss drug 18 to 4 with one abstention. Uncertainty over the risk for heart disease remains a prime concern for panel members.